Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV/Flu-01E Phase 1 in Healthy Volunteers
NCT05970744Phase 1Completed
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSV/Flu-01E in respiratory syncytial virus infection (RSV) (5 arms). Primary endpoint: Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) at 6 months. Started May 2023; status: completed.
02
Drugs
RSV/Flu-01E
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05970744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970744.